Zelira Therapeutics to outline progress of Zenivol™ and HOPE™ at Proactive's medical cannabis webinar on Aug 11

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB:ZLDAF) managing director and chief executive officer Richard Hopkins will outline the company’s plan to launch its its Zenivol™ and HOPE™ range of products into the Australian market by the end of the third quarter 2020.

It is also targeting to launch HOPE™ for autism in Louisiana in the third quarter of 2020.

The developer of clinically validated cannabinoid-derived medicines, is reaching a major milestone as it accelerates its transition from a purely research-based organisation to become a revenue-generating company.

The company generated its maiden revenues from its first US licensing deal in the first quarter of 2020

Zelira is undertaking product development programs targeting specific conditions and human clinical trial programs focused on insomnia, autism and opioid reduction in patients with chronic non-cancer pain.

Product pipeline

Zelira’s commercialisation plans are focused on the launch of up to five different products into global markets in the second half of 2020.

These include the Zenivol™ and HOPE™ range of products in Australia, an aged care formulation, which is expected to launch at the end of the year in the US and a new over-the-counter (OTC) product line that will launch in the US in the next quarter.

Zelira’s commercialisation plans are focused on the launch of up to five different products into global markets in the second half of 2020.

These include the Zenivol™ and HOPE™ range of products in Australia, an aged care formulation, which is expected to launch at the end of the year in the US and a new over-the-counter (OTC) product line that will launch in the US in the next quarter.

The company has developed two proprietary formulations (HOPE™), which have already been launched and generating revenues in Pennsylvania.

Zelira is continuing to progress discussions with third parties aimed at licensing its products, including HOPE™ and Zenivol™, in the US.

Well-funded to accelerate launch of products

The company is well-funded to leverage its unique ‘Launch, Learn and Develop’ model to launch products, generate revenues and progress development of clinically validated medicines.

In early August, Zelira raised a total of A$8.75 million through the oversubscribed placement of 175 million shares at A$0.05 per share, improving the company’s cash position to around A$10.35 million, before costs.

The funds raised will be used to accelerate Zelira’s plans to launch multiple products into global markets and to advance its planned clinical programs.

Webinar registration

Zelira Therapeutics is one of three companies to present at Proactive’s medical cannabis-focused webinar on Tuesday, August 11. The other two companies are: MGC Pharmaceuticals Ltd (ASX:MXC) and Southern Cannabis Holdings.

To register for the August 11 webinar, please click here.

The webinar will also be live-streamed on the Proactive YouTube channel, which can then be viewed anytime following the presentation.

For additional information, please contact John Phillips at Proactive on [email protected] or call 0431 597 771.

Story by ProactiveInvestors